Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.58 |
| ▸ | DHODH | Q02127 | 4/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658192 | 0.85 | PARP1 (0.56) | PARP1DHODHPARP2PKN1PKN2 | |
| SCHEMBL659528 | 0.83 | PARP1 (0.77) | PARP1DHODHPARP2PKN1PKN2 | |
| SCHEMBL658269 | 0.75 | PARP1 (0.70) | PARP1DHODHPARP2PKN1PKN2 | |
| SCHEMBL658640 | 0.74 | PARP1 (0.56) | PARP1DHODHPARP2PKN1PKN2 | |
| SCHEMBL659219 | 0.73 | PARP1 (0.78) | PARP1DHODHPARP2PKN1PKN2 | |
| SCHEMBL18252746 | 0.73 | PARP1 (0.78) | PARP1DHODHPARP2PKN1PKN2 | |
| SCHEMBL6805573 | 0.73 | PARP1 (0.68) | PARP1DHODHPARP2PKN1PKN2 | |
| SCHEMBL659856 | 0.72 | PARP1 (0.56) | PARP1DHODHPARP2PKN1PKN2 | |
| SCHEMBL6805503 | 0.72 | PARP1 (0.81) | PARP1DHODHPARP2PKN1PKN2 | |
| SCHEMBL6805347 | 0.72 | PARP1 (0.63) | PARP1DHODHPARP2PKN1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046303-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2012-02-23 | — | — | US | claimed |
| EP-2183248-A2 | BENZIMIDAZOLE POLY (ADP RIBOSE) POLYMERASE INHIBITORS | Abbott Laboratories (US) | 2010-05-12 | — | — | EP | claimed |
| US-20090030016-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | claimed |
| WO-2009012280-A2 | BENZIMIDAZOLE POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | claimed |
| US-20120046303-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-8067613-B2 | Benzimidazole poly(ADP ribose)polymerase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2183248-A2 | BENZIMIDAZOLE POLY (ADP RIBOSE) POLYMERASE INHIBITORS | Abbott Laboratories (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090030016-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
| WO-2009012280-A2 | BENZIMIDAZOLE POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030016-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885DHODH 1413/4885PARP2 2/4885 |
| US-20120046303-A1 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885DHODH 1413/4885PARP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.